The New England journal of medicine, 2017-08, Vol.377 (9), p.829-838
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- Ist Teil von
- The New England journal of medicine, 2017-08, Vol.377 (9), p.829-838
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK -positive non–small-cell lung cancer. Importantly, it reduced the risk of CNS relapse.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1704795Titel-ID: cdi_proquest_journals_1934032205
- Format
- –
- Schlagworte
- Adult, Aged, 80 and over, Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents - adverse effects, Antineoplastic Agents - therapeutic use, Cancer therapies, Carbazoles - adverse effects, Carbazoles - therapeutic use, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - mortality, Central nervous system, Central Nervous System Neoplasms - drug therapy, Central Nervous System Neoplasms - secondary, Crizotinib, Disease-Free Survival, Drug dosages, Enzyme inhibitors, Female, Follow-Up Studies, Humans, Inhibitor drugs, Intention to Treat Analysis, Kaplan-Meier Estimate, Lung cancer, Lung Neoplasms - drug therapy, Lung Neoplasms - mortality, Lymphoma, Male, Metastasis, Middle Aged, Mutation, Nervous system, Non-small cell lung carcinoma, Oncology, Patients, Piperidines - adverse effects, Piperidines - therapeutic use, Protein Kinase Inhibitors - adverse effects, Protein Kinase Inhibitors - therapeutic use, Protein-tyrosine kinase, Pyrazoles - adverse effects, Pyrazoles - therapeutic use, Pyridines - adverse effects, Pyridines - therapeutic use, Radiation therapy, Receptor Protein-Tyrosine Kinases - analysis, Receptor Protein-Tyrosine Kinases - antagonists & inhibitors, Survival, Systemic diseases, Targeted cancer therapy, Toxicity, Tumors, Young Adult